Dataset from A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00007117
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in
ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to
ALK inhibitors, as evidenced by progression-free survival (PFS).
创建时间：
2026-03-23
